Medroxyprogesterone Acetate: A Promising Treatment for Cervical Cancer

Overview of Cervical Cancer

Cervical cancer is a significant global health issue, ranking as the third most common and third most deadly cancer type. Human papillomavirus (HPV) is a major contributor to cervical intraepithelial neoplasia (CIN), which are precancerous lesions in the cervix. If not addressed, these lesions can progress to cervical cancer.

Research on Medroxyprogesterone Acetate

Researchers at the University of Houston explored the potential of medroxyprogesterone acetate (MPA) as a treatment for cervical cancer. Their findings were published in The American Journal of Pathology.

Study Methodology

The study involved mice genetically modified to express HPV genes. Initially, all mice were treated with estradiol, a form of estrogen, to induce CIN lesions. Subsequently, the mice received either estradiol alone or a combination of estradiol and MPA for different durations to evaluate the treatment’s effectiveness.

Findings of the Study

Mice treated solely with estradiol developed cervical cancer, while those receiving the combination of estradiol and MPA did not progress to cancer. The researchers established two groups for MPA treatment: a long-term prevention group and a short-term prevention group.

The long-term group received the combination treatment for three months, resulting in no instances of cervical cancer. Additionally, MPA treatment was found to reverse existing CIN lesions to less advanced stages. Conversely, some mice in the short-term group, which received MPA for one month followed by two months of estradiol, did develop cervical cancer. Nevertheless, the severity of lesions was reduced in this group as well.

Mechanism of Action

MPA appears to inhibit the development of cervical cancer by promoting the death of dysfunctional cells and preventing the proliferation of abnormal cells.

Impact of Progesterone-Receptor Status

The mice were further divided based on their progesterone-receptor status into progesterone-receptor positive and negative groups. Notably, nearly half of the progesterone-receptor negative mice treated with MPA developed cervical cancer, suggesting that progesterone-receptor status may significantly influence MPA’s effectiveness.

Conclusions and Future Research

Overall, the data indicate that MPA is a promising treatment strategy for CIN lesions, particularly those that are progesterone-receptor positive. Further research is essential to determine the applicability of these results in human clinical trials and to establish optimal treatment durations. Concerns regarding potential vaginal or cervical atrophy associated with MPA usage, although not observed in this study, warrant investigation in future research. Additionally, exploring factors that could enhance the efficacy of MPA treatment will be crucial for advancing cervical cancer therapy.

References

Baik, S., Mehta, F., & Chung, S. (2019). Medroxyprogesterone Acetate Prevention of Cervical Cancer through Progesterone Receptor in a Human Papillomavirus Transgenic Mouse Model. The American Journal Of Pathology. doi: 10.1016/j.ajpath.2019.08.013

Contraceptive drug shows promise for preventing and regressing cervical cancer. (2019). Retrieved 16 November 2019, from https://www.eurekalert.org/pub_releases/2019-11/e-cds110819.php

Estradiol: Side Effects, Dosages, Treatment, Interactions, Warnings. (2019). Retrieved 16 November 2019, from https://www.rxlist.com/consumer_estradiol/drugs-condition.htm

Image by Pexels from Pixabay